Patent Application
20130007910
Polyhydroxylated steroids are regulators of body shape and size in higher organisms. In metazoans intracellular receptors recognize these molecules. Plants however perceive steroids at membranes, using the membrane-integral receptor kinase BRI1.
Signal perception at the cell surface and transduction of this signal to the cell interior is essential to all life forms. Plants have met this challenge in part by evolving membrane-integral receptor kinases (RKs). Many RKs are comprised of an extracellular Leucine-Rich Repeat (LRR1) (Kobe & Deisenhofer, Nature 366, 751-756 (1993)) module and a cytoplasmic kinase domain, connected by a single membrane-spanning helix (Shiu & Bleecker, Proc. Natl. Acad. Sci. U.S.A. 98, 10763-10768 (2001)). Receptors with this architecture (LRR-RKs) initiate signaling pathways that, for example, regulate plant growth (Li & Chory, Cell 90, 929-938 (1997)), development (Clark et al., Cell 89, 575-585 (1997); Nadeau & Sack, Science 296, 1697-1700 (2002)) and interactions with the environment (Gómez-Gómez & Boller, Mol. Cell. 5, 1003-1011 (2000); Zipfel et al., Cell 125, 749-760 (2006); Nishimura et al., Nature 420, 426-429 (2002)). The corresponding ligands range from small molecules (Wang et al., Nature 410, 380-383 (2001)) and peptides (Ogawa et al., Science 319, 294 (2008)); Sugano et al., Nature 463, 241-244 (2010)) to entire proteins.
The LRR-RK BRASSINOSTEROID INSENSITIVE 1 (BRI1) (Li & Chory; Belkhadir & Chory Science 314, 1410-1411 (2006)) controls a steroid signaling pathway essential for plant growth (Vert et al., Annu. Rev. Cell Dev. Biol 21, 177-201 (2005)). While animal steroid receptors are found predominantly in the nucleus (Mangelsdorf et al., Cell 83, 835-839 (1995)), BRI1 is localized at the plasma-membrane and in endosomes (Geldner et al., Genes Dev. 21, 1598-1602 (2007)).
The following model has been proposed for BRI1 activation. In the absence of brassinosteroid, BRI1's kinase domain is kept in a basal state by its auto-inhibitory C-terminal tail, as well as by interaction with the inhibitor protein BKI1. Hormone binding to the extracellular domain of BRI1 (Wang et al., Nature 410, 380-383 (2001); He et al., Science 288, 2360-2363 (2000)) in a region that includes a ˜70 amino acid ‘island’ domain between LRRs 21 and 22 (Kinoshita et al., Nature 433, 167-171 (2005)), causes a change in the receptor (a conformational change in a preformed homodimer (Wang et al., Dev. Cell 8, 855-865 (2005)) or receptor dimerization), leading to autophosphorylation of the BRI1 kinase domain (Wang et al., Plant Cell 17, 1685-1703 (2005)), release of its C-terminal tail and trans-phosphorylation of the inhibitor BKI1 (Wang & Chory, Science 313, 1118-1122 (2006); Jaillais et al., Genes Dev. 25, 232-237 (2011)). BKI1 then dissociates from the membrane, allowing BRI1 to interact with a family of smaller LRR-RKs (Chinchilla, Trends Plant Sci. 14, 535-541 (2009)), including the BRI1 ASSOCIATED KINASE 1 (BAK1). The kinase domains of BRI1 and BAK1 trans-phosphorylate each other on multiple sites (Wang et al., Dev. Cell 15, 220-235 (2008)), and the fully activated receptor triggers downstream signalling events (Kim & Wang, Annu. Rev. Plant Biol. 61, 681-704 (2010)), resulting in major changes in nuclear gene expression.
BRI1 is reminiscent of animal Toll-like innate immunity receptors (TLRs). Indeed several members of the plant LRR-RK family are innate immunity receptors. It was thus expected that the BRI1 ectodomain would form a TLR-like horseshoe structure (Choe et al., Science 309, 581-585 (2005)), and that BRI1 would bind its ligand along a dimer interface, like the TLRs (Liu et al., Science 320, 379-381 (2008); Park et al., Nature 458, 1191-1195 (2009)).
Reported herein is the structure of the ligand binding domain of BRI1 in its free form, and bound to the plant steroid brassinolide. The results show that, unlike TLRs, BRI1 folds into a superhelical assembly, whose interior provides the hormone-binding site. Comparison of the free and hormone-bound structures, combined with genetic data, suggests a novel activation mechanism for BRI1 that is distinct from TLRs.
Provided herein is the structure of BRI1, in both unbound and brassinolide-bound forms. The structure can be used to design novel synthetic brassinosteroid hormones or hormone mimetics with unique properties. In addition, the interactions within the brassinolide-BRI1 complex allow for rational design of modified, e.g., labeled or stabilized, forms of brassinosteroid without affecting the interactions within the complex. The structure also reveals sites on BRI1 that can be used to design BRI1 antagonists. For example, now that the ligand binding and interaction sites are defined, antagonist compounds that can, e.g., block or interfere with ligand or co-receptor binding can be designed. In some embodiments, such antagonists can be used as herbicides or to control the timing of plant growth and development.
Accordingly, in some embodiments, provided herein is an isolated protein comprising a 3-dimensional crystal structure of a BRassinosteroid Insensitive 1 (BRI1) ectodomain as structurally defined by the atomic coordinate data shown in Tables 1 and 2. In some embodiments, the isolated protein comprises a 3-dimensional structure of the BRI1 ectodomain, with a space group C2 and unit cell dimensions a=175.09±0.1 angstrom, b=67.25±0.1 angstrom, c=119.05±0.1, with beta=121.55±0.1. In some embodiments, the isolated protein comprises a 3-dimensional structure of the BRI1 ectodomain as structurally defined by the diagrams shown in
In some embodiments, provided are methods for identifying (screening for) a candidate modulator of BRI1, comprising
In some embodiments, the method further comprises validating the candidate BRI1 modulator by contacting the candidate BRI1 modulator with BRI1 and detecting interaction of the candidate BRI1 modulator with BRI1. In some embodiments, the method further comprises detecting an effect of the candidate BRI1 modulator when contacted with a BRI1 expressing plant, wherein the effect is selected from the group consisting of increasing or decreasing plant biomass and increasing or decreasing the size of vegetative structures in the plant, as compared to a standard control. In some embodiments, the candidate BRI1 modulator interacts with the ligand binding region of BRI1 (e.g. within LRR 21-25). In some embodiments, the candidate BRI1 modulator interacts with the co-receptor interaction region of BRI1 (e.g., within LRR 21-25 and the island domain, see
In some embodiments, provided are methods for identifying (screening for) a candidate modulator of BRI1, comprising
In some embodiments, the method further comprises rational design of the test compound, e.g., based on the BRI1 structure described herein. For example, prior to step (a), the structure of a test compound can be compared to the structure of BRI1 to determine the likelihood of interaction between the test compound BRI1. In some embodiments, the method further comprises detecting an effect of the candidate BRI1 modulator when contacted with a BRI1 expressing plant, wherein the effect is selected from the group consisting of: increasing or decreasing plant biomass and increasing or decreasing the size of vegetative structures in the plant, as compared to a standard control. In some embodiments, the candidate BRI1 modulator interacts with the ligand binding region of BRI1 (e.g. within LRR 21-25). In some embodiments, the candidate BRI1 modulator interacts with the co-receptor interaction region of BRI1 (e.g., within LRR 21-25 and the island domain, see
Also provided are BRI1 modulators. In some embodiments, the BRI1 modulator is identified according to a method as described above. In some embodiments, the BRI1 modulator is brassinosteroid mimetic identified as likely to bind the brassinosteroid binding site of BRI1 as characterized herein (e.g., in
In some embodiments, the BRI1 modulator is a BRI1 inhibitor. In some embodiments, the BRI1 inhibitor interferes with, e.g., ligand binding to BRI1 or co-receptor interaction with BRI1. Such inhibitors can be designed using the BRI1 structural data disclosed herein, e.g., to target BRI1 residues critical for BRI1 ligand binding or co-receptor interaction (see, e.g.,
In some embodiments, the BRI1 modulator is a BRI1 agonist. Such agonists can be designed using the BRI1 structural data disclosed herein, e.g., to target BRI1 residues involved in binding to the natural BRI1 ligand or co-receptor (see, e.g.,
Provided herein is the BRI1 ectodomain structure at 2.5 angstrom resolution. The structure reveals a superhelix of 25 twisted leucine-rich repeats (LRRs), an architecture that is strikingly different from the assembly of LRRs in animal Toll-like receptors. A 70 amino-acid island domain between LRRs 21 and 22 folds back into the interior of the superhelix to create a surface pocket for binding the plant hormone brassinolide. Known loss- and gain-of-function mutations closely map to what is herein revealed to be the hormone-binding site. The structure described herein indicates that steroid binding to BRI1 generates a docking platform for a co-receptor that is required for receptor activation. The findings have mechanistic implications for hormone, developmental, and innate immunity signaling pathways in plants that use similar receptors.
The structure of the BRI1 ectodomain offers several new insights, and its twisted shape will likely characterize the architecture of many plant LRR-RKs. The presence of a folded domain as an LRR insertion is likely an adaptation to recognize a small molecule ligand, a challenge that smaller LRR proteins have met by generating loop insertions into their capping motifs (Han et al., Science 321, 1834-1837 (2008)). The unusual superhelical structure of BRI1 and its fascinating mode of ligand recognition provides insights into how steroids can be sensed at membranes and rationalizes a large set of genetic and biochemical findings.
The structure of the BRI1-brassinolide complex is informative about the molecular interactions between the ligand and receptor. This for the first time explains why certain chemical modifications of brassinolide are tolerated, while others are inactivated, and why animal steroid hormones with similar structure are not effective in plants (see, e.g., Back and Pharis (2003) J. Plant Growth Regul. 22:350.
In addition, comparison of the brassinolide-bound and unbound structures are informative of the mechanism of activation. Brassinolide binding creates a docking platform in BRI1, which is recognized by the extracellular LRR domain of BRI1 Associated Kinase 1 (BAK1). BAK1 thus can act as a co-receptor for activation of the BRI1 signaling pathway.
Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art. See, e.g., Lackie, D
The term “BRI1” refers to “Brassinolide Insensitive 1” proteins, homologs (e.g., orthologs from different species or paralogs), BRI1 fragments having BRI1 activity, and BRI1 variants having substantial identity to a naturally occurring BRI1 with BRI1 activity. BRI1 activities include, e.g., brassinosteroid binding, phosphorylation of BAK1 and initiation of the BR signaling pathway, increasing plant mass, and increasing the size of vegetative structures.
A “brassinosteroid analog” or “brassinosteroid mimetic” is a compound that has a similar structural interaction with BRI1 as a brassinosteroid. Brassinosteroid mimetics include “brassinolide analogs” and “brassinolide mimetics.” In some cases, the brassinosteroid mimetic also has brassinosteroid activity and activates BRI1 signaling. Brassinosteroid mimetics can be steroidal or non-steroidal, and include B-ring analogs, side chain analogs (e.g., C-3, C-24, C-25, and C-26 side chain analogs), and methyl ether analogues. Brassinosteroid mimetics also include compounds that are designed considering the BRI1 structure provided herein, e.g., to have a similar interaction with BRI1 as brassinolide, as shown in
A “label” or a “detectable moiety” is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, chemical, or other physical means. For example, useful labels include 32P, fluorescent dyes, electron-dense reagents, enzymes, biotin, digoxigenin, or haptens and proteins or other entities which can be made detectable, e.g., by incorporating a radiolabel into a peptide or antibody specifically reactive with a target peptide. Any method known in the art for conjugating a compound or protein to the label may be employed, e.g., using methods described in Hermanson, Bioconjugate Techniques 1996, Academic Press, Inc., San Diego.
A “labeled” or “tagged” molecule (e.g., compound, modulator, protein, or antibody) is one that is bound, either covalently, through a linker or a chemical bond, or noncovalently, through ionic, van der Waals, electrostatic, or hydrogen bonds to a label such that the presence of the molecule may be detected by detecting the presence of the label bound to the molecule.
“Nucleic acid” refers to deoxyribonucleotides or ribonucleotides and polymers thereof in either single- or double-stranded form, and complements thereof. The term “polynucleotide” refers to a linear sequence of nucleotides. The term “nucleotide” typically refers to a single unit of a polynucleotide, i.e., a monomer. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified versions thereof. Examples of polynucleotides contemplated herein include single and double stranded DNA, single and double stranded RNA (including siRNA), and hybrid molecules having mixtures of single and double stranded DNA and RNA.
The words “protein”, “peptide”, and “polypeptide” are used interchangeably to denote an amino acid polymer or a set of two or more interacting or bound amino acid polymers. The terms apply to amino acid polymers in which one or more amino acid residue is an artificial chemical mimetic of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers, those containing modified residues, and non-naturally occurring amino acid polymer.
The term “amino acid” refers to naturally occurring and synthetic amino acids, as well as amino acid analogs and amino acid mimetics that function similarly to the naturally occurring amino acids. Naturally occurring amino acids are those encoded by the genetic code, as well as those amino acids that are later modified, e.g., hydroxyproline, γ-carboxyglutamate, and O-phosphoserine. Amino acid analogs refers to compounds that have the same basic chemical structure as a naturally occurring amino acid, e.g., an a carbon that is bound to a hydrogen, a carboxyl group, an amino group, and an R group, e.g., homoserine, norleucine, methionine sulfoxide, methionine methyl sulfonium. Such analogs may have modified R groups (e.g., norleucine) or modified peptide backbones, but retain the same basic chemical structure as a naturally occurring amino acid. Amino acid mimetics refers to chemical compounds that have a structure that is different from the general chemical structure of an amino acid, but that functions similarly to a naturally occurring amino acid.
Amino acids may be referred to herein by either their commonly known three letter symbols or by the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides, likewise, may be referred to by their commonly accepted single-letter codes.
“Conservatively modified variants” applies to both amino acid and nucleic acid sequences. With respect to particular nucleic acid sequences, conservatively modified variants refers to those nucleic acids which encode identical or essentially identical amino acid sequences, or where the nucleic acid does not encode an amino acid sequence, to essentially identical or associated, e.g., naturally contiguous, sequences. Because of the degeneracy of the genetic code, a large number of functionally identical nucleic acids encode most proteins. For instance, the codons GCA, GCC, GCG and GCU all encode the amino acid alanine. Thus, at every position where an alanine is specified by a codon, the codon can be altered to another of the corresponding codons described without altering the encoded polypeptide. Such nucleic acid variations are “silent variations,” which are one species of conservatively modified variations. Every nucleic acid sequence herein which encodes a polypeptide also describes silent variations of the nucleic acid. One of skill will recognize that in certain contexts each codon in a nucleic acid (except AUG, which is ordinarily the only codon for methionine, and TGG, which is ordinarily the only codon for tryptophan) can be modified to yield a functionally identical molecule. Accordingly, often silent variations of a nucleic acid which encodes a polypeptide is implicit in a described sequence with respect to the expression product, but not with respect to actual probe sequences.
As to amino acid sequences, one of skill will recognize that individual substitutions, deletions or additions to a nucleic acid, peptide, polypeptide, or protein sequence which alters, adds or deletes a single amino acid or a small percentage of amino acids in the encoded sequence is a “conservatively modified variant” where the alteration results in the substitution of an amino acid with a chemically similar amino acid. Conservative substitution tables providing functionally similar amino acids are well known in the art. Such conservatively modified variants are in addition to and do not exclude polymorphic variants, interspecies homologs, and alleles of the invention. The following amino acids are typically conservative substitutions for one another: 1) Alanine (A), Glycine (G); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); 7) Serine (S), Threonine (T); and 8) Cysteine (C), Methionine (M) (see, e.g., Creighton, Proteins (1984)).
Two nucleic acid sequences or polypeptides are said to be “identical” if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence as described below. The term “complementary to” is used herein to mean that the sequence is complementary to all or a portion of a reference polynucleotide sequence.
Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman, Add. APL. Math. 2:482 (1981), by the homology alignment algorithm of Needle man and Wunsch, J. Mol. Biol. 48:443 (1970), by the search for similarity method of Pearson and Lipman, Proc. Natl. Acad. Sci. U.S.A. 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, BLAST, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by inspection
The terms “identical” or “percent identity,” in the context of two or more nucleic acids, or two or more polypeptides, refer to two or more sequences or subsequences that are the same or have a specified percentage of nucleotides, or amino acids, that are the same (i.e., about 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or higher identity over a specified region, when compared and aligned for maximum correspondence over a comparison window or designated region) as measured using a BLAST or BLAST 2.0 sequence comparison algorithms with default parameters, or by manual alignment and visual inspection. See e.g., the NCBI web site at ncbi.nlm.nih.gov/BLAST. Such sequences are then said to be “substantially identical.” This definition also refers to, or may be applied to, the compliment of a nucleotide test sequence. The definition also includes sequences that have deletions and/or additions, as well as those that have substitutions. As described below, the preferred algorithms can account for gaps and the like. Preferably, identity exists over a region comprising a ligand binding site or interaction domain, or a sequence that is at least about 25 amino acids or nucleotides in length, or over a region that is 50-100 amino acids or nucleotides in length.
The term “recombinant” when used with reference, e.g., to an organism, cell, nucleic acid, protein, or vector, indicates that the organism, cell, nucleic acid, protein or vector has been modified by the introduction of a heterologous nucleic acid or protein or the alteration of a native nucleic acid or protein, or that the cell is derived from a cell so modified. Thus, for example, recombinant cells and organisms express genes that are not found within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all.
A polynucleotide or polypeptide is “heterologous to” a second polynucleotide or polypeptide sequence if it originates from a foreign species, or, if from the same species, is modified by human action from its original form. For example, a promoter operably linked to a heterologous coding sequence refers to a coding sequence from a species different from that from which the promoter was derived, or, if from the same species, a coding sequence which is different from any naturally occurring allelic variants.
An “expression cassette” refers to a nucleic acid construct, which when introduced into a host cell, results in transcription and/or translation of a RNA or polypeptide, respectively. Antisense or sense constructs that are not or cannot be translated are included by this definition.
The term “plant” includes whole plants, shoot vegetative organs/structures (e.g. leaves, stems and tubers), roots, flowers and floral organs/structures (e.g. bracts, sepals, petals, stamens, carpels, anthers and ovules), seeds (including embryo, endosperm, and seed coat) and fruit (the mature ovary), plant tissue (e.g. vascular tissue, ground tissue, and the like) and cells (e.g. guard cells, egg cells, trichomes and the like), and progeny of same. The class of plants that can be used in the method of the invention is generally as broad as the class of higher and lower plants amenable to transformation techniques, including angiosperms (monocotyledonous and dicotyledonous plants), gymnosperms, ferns, bryophytes, and multicellular algae. It includes plants of a variety of ploidy levels, including aneuploid, polyploid, diploid, haploid and hemizygous.
The term “specifically bind” refers to a compound (e.g., BRI1-binding compound) that binds to a target with at least 2-fold greater affinity than non-target compounds, e.g., at least 4-fold, 5-fold, 6-fold, 7-fold, 8-fold, 9-fold, 10-fold, 20-fold, 25-fold, 50-fold, or 100-fold greater affinity.
The term “compete”, as used regarding a BRI1 ligand, modulator, or interacting protein, means that a first compound competes for binding to BRI1 with a second compound, where binding of the first compound to its site on BRI1 is detectably decreased in the presence of the second compound compared to the binding of the first compound in the absence of the second compound. The alternative, where the binding of the second compound to its site on BRI1 is also detectably decreased in the presence of the first compound, can, but need not be the case. That is, a first compound can inhibit the binding of a second compound to its site without that second compound inhibiting the binding of the first compound to its respective site. However, where each compound detectably inhibits the binding of the other to BRI1, whether to the same, greater, or lesser extent, the compounds are said to “cross-compete” with each other for binding of their respective site(s).
The term “modulator” includes inhibitors and activators. Inhibitors are agents that, e.g., inhibit expression or bind to, partially or totally block stimulation or down regulate the activity of the described target protein, e.g., BRI1. Activators are agents that, e.g., induce or activate the expression of a described target protein or bind to, stimulate, or up regulate the activity of described target protein, e.g., BRI1. Modulators include naturally occurring and synthetic ligands, antagonists and agonists (e.g., small chemical molecules, steroids, antibodies, etc. that affect target activity). Assays for inhibitors and activators include, e.g., applying candidate modulator compounds to cells expressing the described target protein (e.g., BRI1 expressing cells) and then determining the functional effects on the described target protein activity. Samples or assays comprising described target protein that are treated with a potential activator, inhibitor, or modulator are compared to control samples without the inhibitor, activator, or modulator to examine the extent of effect. Control samples (untreated with modulators) can be assigned a relative activity value of 100%.
The terms “agonist,” “activator,” “inducer” and like terms refer to molecules that increase activity or expression as compared to a control. Agonists are agents that, e.g., bind to, stimulate, increase, activate, enhance activation, sensitize or upregulate the activity of the target. The expression or activity can be increased 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% 100% or more than that of a control (i.e., 110%, 120%, etc.). In certain instances, the activation is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more in comparison to a control.
The terms “inhibitor,” “repressor” or “antagonist” or “downregulator” interchangeably refer to a substance that results in a detectably lower expression or activity level as compared to a control. The inhibited expression or activity can be 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or less than that in a control. In certain instances, the inhibition is 1.5-fold, 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, or more in comparison to a control.
A “control” sample or value refers to a sample that serves as a reference, usually a known reference, for comparison to a test sample. For example, a test sample can be taken from a test condition, e.g., in the presence of a test compound (e.g., candidate BRI1 modulator), and compared to samples from known conditions, e.g., in the absence of the test compound (negative control), or in the presence of a known compound (positive control, e.g. brassinolide or other known BRI1 modulator). A control can also represent an average value gathered from a number of tests or results. One of skill in the art will recognize that controls can be designed for assessment of any number of parameters. Controls can be designed for in vitro applications, e.g., for comparison to the binding activity and location of various candidate BRI1 modulators. Controls can also be designed for in situ or in vivo applications, e.g., for comparison to the effect of candidate BRI1 modulators on a BRI1-expressing plant or plant part. One of skill in the art will understand which controls are valuable in a given situation and be able to analyze data based on comparisons to control values. Controls are also valuable for determining the significance of data. For example, if values for a given parameter are widely variant in controls, variation in test samples will not be considered as significant.
As described below in detail, we have crystallized the BRI1 ectodomain and island domain in unbound and brassinolide-bound forms (see, e.g., Tables 1 and 2). Several parameters can be used to uniquely describe the symmetry and geometrical characteristics of a crystal. These include the space group (symmetry), the three unit cell axial lengths “a”, “b”, and “c”, and the three unit cell interaxial angles “α”, “β”, and “γ” (geometry). “Unit cell axial length” and “unit cell interaxial angle” are terms of art that refer to the three-dimensional geometrical characteristics of the unit cell, in essence its length, width, and height, and whether the building block is a perpendicular or oblique parallelepiped. The unit cell axial lengths and interaxial angles can vary by as much as ±10% without substantively altering the arrangement of the molecules within the unit cell. Thus, reference to each of the unit cell axial lengths and interaxial angles as being “about” a particular value is to be understood to mean that any combination of these unit cell axial lengths and interaxial angles can vary by as much as ±10% from the stated values.
BRI1, BRI1 domains, BRI1 interacting proteins (e.g., BAK1, or BAK1-like proteins or domains), and the like can be recombinantly expressed according to methods known in the art (see, e.g., Mus-Vetaux, Heterologous Expression of Membrane Proteins (2009); Glorioso et al. Expression of Heterologous Genes in Eukaryotic Systems, Methods in Enzymology Vol. 306 (1999)).
The sequence and domains for BRI1 and BAK1 are publically available at the NCBI website (ncbi.nlm.nih.org) for several plant species. For example, the Arabidopsis Uniprot accession number for BRI1 is O22476 (see also SEQ ID NO:1). One of skill will understand that homologs (e.g., orthologs from other species or paralogs within the same species such as BRI3) can be optimally aligned so that conserved residues can be located on the respective BRI1 proteins (see, e.g., Holton et al. (2007) Plant Cell 19:1709; Cano-Delgado et al. (2004) Development 131:5341).
Provided herein are recombinant expression cassettes comprising a promoter sequence operably linked to a nucleic acid sequence encoding a desired polypeptide sequence (e.g., BRI1, BRI1 variants and species homologs, a BRI1 domain, a BRI1-interacting protein, etc.). In some embodiments, the BRI1 domain is an ectodomain. In some embodiments, the BRI1-interacting protein is BAK1.
To use isolated sequences in the above techniques, recombinant DNA vectors suitable for transformation of cells can be prepared. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature, e.g., Weising et al., Ann. Rev. Genet. 22:421-477 (1988). Methods for expression in insect cells are described in more detail in the examples. Any cell type can be used for overexpression and protein production, as will be familiar to one of skill in the art, and kits for protein expression and purification are commercially available (e.g., from Invitrogen). A DNA sequence coding for the desired polypeptide, for example a cDNA sequence encoding a full-length protein, can be combined with transcriptional and translational initiation regulatory sequences which will direct the transcription of the sequence from the gene in the intended cell. In the context of the present invention, protein expression for the purpose of in situ or in vivo functional studies is typically carried out in plant cells, plant tissues, or whole plants (transgenic plants).
For example, a plant promoter can be employed which will direct expression of the gene in all tissues of a regenerated plant. Such promoters are referred to herein as “constitutive” promoters and are active under most environmental conditions and states of development or cell differentiation. Alternatively, the plant promoter can direct expression of the polynucleotide of the invention in a specific tissue (tissue-specific promoters, organ-specific promoters) or specific environmental condition (inducible promoters).
A polyadenylation region at the 3′-end of the coding region can be included. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA.
The vector comprising the sequences (e.g., promoters or coding regions) from genes of the invention will typically comprise a marker gene that confers a selectable phenotype on plant cells. For example, the marker may encode biocide resistance, particularly antibiotic resistance, such as resistance to kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosulfuron or Basta.
Coding sequences, e.g., nucleic acid sequences that encode the BRI1 protein, can expressed recombinantly in plant cells. A variety of different expression constructs, such as expression cassettes and vectors suitable for transformation of plant cells can be prepared. A DNA sequence coding for a polypeptide described in the present invention, e.g., a cDNA sequence encoding BRI1, or a BRI1 domain, can be combined with cis-acting (promoter and enhancer) transcriptional regulatory sequences to direct the timing, tissue type and levels of transcription in the intended tissues of the transformed plant. Translational control elements can also be used.
The invention provides a nucleic acid encoding a BRI1 polypeptide operably linked to a promoter which is capable of driving the transcription of the coding sequence in plants. The promoter can be, e.g., derived from plant or viral sources. The promoter can be, e.g., constitutively active, inducible, or tissue specific. In construction of recombinant expression cassettes, vectors, transgenics, of the invention, different promoters can be chosen and employed to differentially direct gene expression, e.g., in some or all tissues of a plant.
Further provided are methods of generating transgenic plants that express recombinant BRI1 (or other desired protein). Appropriate expression cassettes can be introduced into the genome of the desired plant host by a variety of conventional techniques. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation and microinjection of plant cell protoplasts, or the DNA constructs can be introduced directly to plant tissue using biolistics, e.g., DNA particle bombardment.
Microinjection techniques are known in the art and well described in the scientific and patent literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski et al. Embo J. 3:2717-2722 (1984). Electroporation techniques are described in Fromm et al. Proc. Natl. Acad. Sci. USA 82:5824 (1985). Biolistic transformation techniques are described in Klein et al. Nature 327:70-73 (1987).
Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional Agrobacterium tumefaciens host vector. The virulence functions of the Agrobacterium tumefaciens host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria. Agrobacterium tumefaciens-mediated transformation techniques, including disarming and use of binary vectors, are well described in the scientific literature. See, for example Horsch et al. Science 233:496-498 (1984), and Fraley et al. Proc. Natl. Acad. Sci. USA 80:4803 (1983) and Gene Transfer to Plants, Potrykus, ed. (Springer-Verlag, Berlin 1995).
Transformed plant cells which are derived by any of the above transformation techniques can be cultured to regenerate a whole plant which possesses a desired phenotype. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker that has been introduced together with the desired nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans et al., Protoplasts Isolation and Culture, Handbook of Plant Cell Culture, pp. 124-176, MacMillilan Publishing Company, New York, 1983; and Binding, Regeneration of Plants, Plant Protoplasts, pp. 21-73, CRC Press, Boca Raton, 1985. Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee et al., Ann. Rev, of Plant Phys. 38:467-486 (1987).
The above techniques can be used to produce transgenic plants in any plant species, including species from the genera Anacardium, Arachis, Asparagus, Atropa, Avena, Brassica, Chlamydomonas, Chlorella, Citrus, Citrullus, Capsicum, Carthamus, Cocos, Coffea, Cucumis, Cucurbita, Cyrtomium, Daucus, Elaeis, Fragaria, Glycine, Gossypium, Helianthus, Heterocallis, Hordeum, Hyoscyamus, Lactuca, Laminaria, Linum, Lolium, Lupinus, Lycopersicon, Macrocystis, Malus, Manihot, Majorana, Medicago, Nereocystis, Nicotiana, Olea, Oryza, Osmunda, Panieum, Pannesetum, Persea, Phaseolus, Pistachia, Pisum, Pyrus, Polypodium, Prunus, Pteridium, Raphanus, Ricinus, Secale, Senecio, Sinapis, Solanum, Sorghum, Theobromus, Trigonella, Triticum, Vicia, Vitis, Vigna, and Zea.
A. BRI1 Activity Assays
BRI1 activities include binding to brassinosteroids (e.g. brassinolide and compounds disclosed in Back & Pharis (2003) J. Plant Growth Regul. 22:350), BAK1, and BAK1-like proteins. BRI1 modulators can also bind BRI1, e.g., to interfere with ligand or coreceptor binding (antagonist), or to mimic or improve ligand or coreceptor binding (agonist).
The binding affinity of a compound, e.g., a candidate BRI1 modulator, can be defined in terms of the comparative dissociation constants (Kd) of the compound for target (e.g., BRI1), as compared to the dissociation constant with respect to the compound and other materials in the environment or unrelated molecules in general. Typically, the Kd for the compound with respect to the unrelated material will be at least 2-fold, 3-fold, 4-fold, 5-fold, 10-fold, 20-fold, 50-fold, 100-fold, 200-fold or higher than Kd with respect to the target.
The desired affinity for an compound, e.g., high (pM to low nM), medium (low nM to 100 nM), or low (about 100 nM or higher), can differ depending upon the BRI1 binding site and the targeted activity. Compounds having different affinities can be used for different applications.
A compound will typically bind with a Kd of less than about 1000 nM, e.g., less than 250, 100, 50, 20 or lower nM. In some embodiments, the Kd of the compound is less than 15, 10, 5, or 1 nM. The value of the dissociation constant (Kd) can be determined by well-known methods, and can be computed even for complex mixtures by methods as disclosed, e.g., in Caceci et al., Byte (1984) 9:340-362; and as reviewed in Ernst et al. Determination of Equilibrium Dissociation Constants, Therapeutic Monoclonal Antibodies (Wiley & Sons ed. 2009).
The Kd, Kon, and Koff can also be determined using surface plasmon resonance (SPR), e.g., as measured by using a Biacore T100 system. SPR techniques are reviewed, e.g., in Hahnfeld et al. Determination of Kinetic Data Using SPR Biosensors, Molecular Diagnosis of Infectious Diseases (2004). In a typical SPR experiment, one interactant (target or targeting agent) is immobilized on an SPR-active, gold-coated glass slide in a flow cell, and a sample containing the other interactant is introduced to flow across the surface. When light of a given frequency is shined on the surface, the changes to the optical reflectivity of the gold indicate binding, and the kinetics of binding.
Binding affinity can also be determined by anchoring a biotinylated interactant to a streptaviden (SA) sensor chip. The other interactant is then contacted with the chip and detected, e.g., as described in Abdessamad et al. (2002) Nuc. Acids Res. 30:e45.
BRI1 activities also include BAK1 phosphorylation and initiation of the brassinosteroid signaling pathway. Assays for detection of BRI1 signal transduction are described, e.g., in Wang et al. (2006) Cell Res. 16:427.
Methods for detecting increased plant mass or increased size of vegetative structure can include the steps of exposing a BRI1 expressing plant with a BRI1 agonist and detecting an increase in the amount of plant mass and/or size of vegetative structures (e.g., stems, leaves) as compared to a standard control. An appropriate standard control can be selected by one of skill in the art, e.g., a plant that does not express BRI1, a plant that is not exposed to a BRI1 agonist, or a plant that is exposed to a BRI1 antagonist.
BRI1 activity can be measured using a leaf lamina inclination assay (Baron et al. (1998) Phytochemistry 49:1849; Back & Pharis (2003) J. Plant Growth RegulI 22:350). In the absence of brassinosteroid signaling, the leaf lamina is nearly vertical, e.g., 160-170 degrees, while strong brassinosteroid signaling results in a leaf lamina angle of about 60 degrees.
In some embodiments, the invention provides methods of identifying a BRI1 modulator comprising contacting a candidate compound and BRI1, and detecting BRI1 activity, wherein a change in BRI1 activity in the presence of the candidate compared to a standard control indicates that the candidate compound is a BRI1 modulator. In some embodiments, the BRI1 is expressed in a plant, and the contacting step involves contacting the candidate compound with the plant. In some embodiments, the BRI1 modulator is a BRI1 inhibitor, and in some embodiments, the BRI1 modulator is a BRI1 agonist.
In some embodiments, the standard control lacks the candidate compound. In some embodiments, e.g., for determining whether the candidate compound is a BRI1 agonist, the standard control is brassinolide, or another known BRI1 agonist. In some embodiments, e.g., for determining whether the candidate compound is a BRI1 antagonist, the method further includes a step of exposing the BRI1 to an agonist, and determining the ability of the candidate compound to interfere with BRI1 signaling.
The presently provided structural data allows one of skill to more accurately design and/or identify potential BRI1 modulators, e.g., based on known modulators, the structural elements of the ligand-binding site, or the structural elements of the co-receptor interaction site.
B. BRI1 Variants and Modulators
Provided herein are BRI1 variants and modulators that can be used for comparison, e.g., as controls, in the screening methods described herein. For example, the activity of a candidate BRI1 modulator can be compared to that of a known BRI1 modulator. The activity of a candidate BRI1 modulator can also be compared to the activity of a BRI1 variant, e.g., a gain-of-function mutant (Haliday et al. 2006 Plant J.) or loss-of-function mutant (Grove et al. 1979 Nature; Nam & Li 2002 Cell).
BRI1 variants include loss-of-function mutants 102 (Thr75011e), 6 (Gly644Asp), and gain-of-function mutation sud1 (Gly643Glu) (see, e.g., Noguchi et al. (1999) Plant Physiol 121:743; Dievart et al. (2006) Funct Plant Biol. 33:723; Friedrichsen et al. (2000) Plant Physiol 123:1247). For example, a candidate modulator that causes a dwarf phenotype similar to bri1-102 compared to an untreated BRI1 wild-type plant can be considered a BRI1 antagonist or inhibitor. A candidate modulator that causes a larger (increased biomass, increase vegetative structure size) phenotype, similar to sud1, compared to an untreated BRI1 wild-type plant can be considered a BRI agonist or activator.
Compounds with BRI1 agonist activity include, but are not limited to, the steroidal and non-steroidal brassinolide-like compounds disclosed in Back & Pharis (2003) J. Plant Growth Regul 22:350; and the brassinolide B-ring analogs 7-azabrassinolide, 7-thiabrassinolide, 6-deoxybrassinolide, B-homocastasterone, 6-methylidene-castasterone and 6-methylidene-B-homocastasterone (Baron et al. (1998) Phytochemistry 49:1849). The activity of a candidate BRI1 modulator can be compared with these BRI1 agonists, as well as brassinolide itself, to determine if the candidate modulator is also an agonist. BRI1 antagonists include BKI, which can be used for comparison, e.g., to determine if a candidate modulator is an antagonist.
C. Rational Design of BRI1 Modulators
Hormones, hormone mimetics, and other modulating compounds with BRI1 regulating activity can be identified using structure coordinates of the BRI1 ectodomain, BRI1 island domain, or other BRI1 domains, as disclosed herein. Such methods of screening can comprise: (a) generating structure coordinates of a three-dimensional structure of a test substance; and (b) superimposing the structure coordinates of (a) onto all or some of the structure coordinates of BRI1 in the same coordinate system so as to evaluate their state of fitting. Specifically, such a method involves fitting the structure coordinates of BRI1 to structure coordinates representing a three-dimensional structure of any test substance on a computer, expressing their state of fitting numerically using, for example, empirical scoring functions as indices, and then evaluating the binding ability of the test substance to BRI1.
The structure coordinates of BRI1 are used, the shape of BRI1 binding site or interaction site is assigned, and then a compound that can bind to the site can be subjected to computer screening using commercial package software such as DOCK (Ewing et al., J. COMP. AIDED MOL. DES. 15:411-428 (2001)), AutoDock (Morris et al., J. COMPUTATIONAL CHEM. 19:1639-1662 (1998)), Ludi, or LigandFit. For example, amino acid residues and domains in BRI1 that can interact with the natural brassinolide ligand are shown, e.g., in Table 2 and
The step of superimposing structure coordinates of a test substance onto all or some of the structure coordinates of BRI1 in the same coordinate system so as to evaluate their state of fitting can also be carried out with the above commercial software. Any appropriate modeling software can be used, as long as it makes a simulation of the docking procedure of a ligand or other modulator to a protein possible on a computer. For example, software programs such as DOCK, FlexX (Tripos, Inc.), LigandFit (Accelrys Inc.), or Ludi (Accelrys Inc.) can be used.
In some embodiments, an initial step is positioning of a virtual spherical body referred to as a sphere, using a SPHGEN program, near a position to which a candidate BRI1 modulator (agonist or antagonist) is likely to bind. This sphere functions as an anchor for docking of the modulator. In addition, sites at which spheres are generated can be limited to specific pockets or specific clefts, or spheres can be generated at a plurality of sites.
Next, grids are generated at a portion and the periphery of the desired BRI1 position using a GRID program, so as to express an electronic and steric environment for receptor residues within an assigned range as a scalar value on each grid. In addition, the force field of AMBER (Pearlman, et al., COMP. PHYS. COMMUN. 91:1-41 (1995)) or the like is utilized to calculate each grid value. Furthermore, depending on the shape, adjustment can also be made by altering grid information so as to express docking of a compound in a more realistic form.
Next, a search can be conducted on a compound database. Using the DOCK program, a compound that is takes a three-dimensional conformation so as not to repel steric elements or electronic elements on the grids is searched for. The three dimensional conformation of the docked compound is optimized by a conformation-generating function integrated in the DOCK program. Whether or not appropriate docking is finally conducted can be further determined based on empirical judgment, e.g., using scores at the time of docking, visual observation, and in situ screening. In this manner, a series of selected compound groups judged to be able to appropriately conduct docking can be considered as substances likely to modulate BRI1 activity (agonist or antagonist) at a certain probability.
The above method promotes more efficient, rational development of BRI1 modulators. Specifically, predicting the arrangement of structure coordinates that fit the properties and shapes of the interaction sites of the BRI1-ligand complex, or the BRI1-BAK1 complex, and the selection by calculation of a compound having a structure capable of agreeing with the putative structure coordinates, make it possible to efficiently select an activity-controlling substance specific to BRI1 from among many compounds.
Likely modulator compounds obtained from the modeling methods can then be validated using any of the screening methods described above, e.g., by contacting the likely modulator compound with a plant expressing BRI1, and determining the effect of the compound on the plant.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entireties for all purposes.
The entire BRI1 ectodomain was produced as a StrepII-9xHis fusion protein by secreted expression in baculovirus-infected Trichoplusia ni cells. The protein was harvested 4 d post-infection by ultrafiltration and purified by sequential Co2+ and Strep affinity chromatography, and by gel filtration. BRI1 was concentrated to 15 mg/ml and crystallized by vapor diffusion using a reservoir solution containing 14% PEG 4,000, 0.2 M (NH4)2SO4, 0.1 M citric acid (pH 4.0). A complex with the plant steroid brassinolide was obtained by co-crystallization. Diffraction data to 2.5 Å resolution were collected on a rotating anode X-ray generator and at beam-line 8.2.1 of the Advanced Light Source (ALS), Berkeley. The structure was solved using the SIRAS method. Data and refinement statistics are summarized in Table 1.
Protein expression and purification. A synthetic gene comprising the entire BRI1 ectodomain (residues 29-788) and codon optimized for expression in Trichoplusia ni was synthesized by Geneart (Regensburg, Germany). The gene was cloned into a modified pBAC-6 transfer vector (Novagen), providing a glycoprotein 64 signal peptide and a C-terminal TEV (tobacco etch virus protease) cleavable Strep-9xHis tandem affinity tag. Recombinant baculoviruses were generated by co-transfecting the transfer vector with linearized baculovirus DNA (ProFold-ER1, AB vector, San Diego, USA) and amplified in Sf9 cells. The fusion protein was expressed in Hi5 cells using a multiplicity of infection of 5, and harvested from the medium 4 days post infection by tangential flow filtration using a 30 kDa MWCO (molecular weight cut-off) filter membrane (GE Healthcare). BRI1 was purified by sequential Co2+ (His select gel, Sigma) and Strep (Strep-Tactin Superflow high-capacity, IBA, Gottingen, Germany) affinity chromatography. Next, the tandem affinity tag was removed by incubating purified BRI1 with recombinant TEV protease in 1:100 molar ratio. The cleaved tag and the protease were separated from BRI1 by size exclusion chromatography on a Superdex 200 HR10/30 column (GE Healthcare) equilibrated in 20 mM Hepes pH 7.5, 100 mM NaCl, 1 mM EDTA). Monomeric peak fractions were concentrated to ˜15 mg/mL and snap frozen in liquid nitrogen. About 50-80 μg of purified BRI1 could be obtained from 1 litre of insect cell culture.
Crystallization and data collection. Initial crystals of BRI1 appeared in 18% PEG 4,000, 0.8 M KCl using the counter diffusion method. Diffraction quality crystals of about 300×80×600 um could be grown after multiple rounds of microseeding at room-temperature by vapor diffusion in hanging drops composed of 1.25 μL of protein solution (15 mg/mL) and 1.25 μL of crystallization buffer (14% PEG 4,000, 0.2 M (NH4)2SO4, 0.1 M citric acid pH 4.0) suspended above 1.0 mL of the mother liquor as the reservoir solution. For structure solution crystals were stabilized, derivatized and cryo-protected by serial transfer into 16% PEG 4,000, 1.7 M Na malonate pH (4.0) and 0.5 M NaI, and cryo-cooled in liquid nitrogen. Single-wavelength anomalous diffraction (SAD) data to 2.9 Å resolution were collected on a Rigaku MicroMax rotating anode equipped with a copper filament, osmic mirrors and an R-AXIS IV++ detector. Native crystals were transferred to a cryo-protective solution containing 16% PEG 4,000 and 1.7 M Na malonate (pH 4.0) and flash-cooled in liquid nitrogen. An isomorphous native dataset to 2.5 Å was collected at beam-line 8.2.1 of the Advanced Light Source (ALS), Berkeley. The hormone-bound structure was obtained by dissolving brassinolide (Chemiclones Inc., Waterloo, Canada) to a concentration of 1 mM in 100% DMSO. This stock solution was diluted to a final concentration of about 50 μM in protein storage buffer (20 mM Hepes pH 7.5, 100 mM NaCl, 1 mM EDTA). Purified BRI1 protein was added to a final concentration of about 12.5 μM (1.5 mg/mL) and the mixture was incubated at room-temperature for 16 h. Next, the complex was re-concentrated to 18 mg/mL, and immediately used for crystallization. Crystals appeared under similar conditions as established for the unbound form and diffracted again to about 2.5 Å. Data processing and scaling was done with XDS (Kabsch, J. Appl. Crystallogr. 26, 795-800 (1993)) (version: May 2010) (Table 1).
Structure Solution and Refinement. The program XPREP (Bruker AXS) was used to scale native and derivative data for SIRAS (single isomorphous replacement with anomalous scattering) analysis. Using data between 30-3.7 Å, SHELXD (Sheldrick, Crystallogr. 64, 112-122 (2008)) located 52 iodine sites (CC All/Weak 42.50/19.82). 16 consistent sites were input into the program SHARP (Bricogne et al., Acta Crystallogr. D Biol. Crystallogr. 59, 2023-2030 (2003)) for phasing and identification of 10 additional sites at 2.9 Å resolution (
Size-exclusion chromatography was performed using a Superdex 200 HR 10/30 column (GE Healthcare) pre-equilibrated in 25 mM citric acid/sodium citrate buffer (pH 4.5), 100 mM NaCl. 100 μL of sample (5 mg/mL) was loaded onto the column and elution at 0.6 mL/min was monitored by ultraviolet absorbance at 280 nm. Incubation with brassinolide was performed as described in the crystallization section.
Homology Modeling of the AtBAK1 ectodomain (residues 27-227; Uniprot accession Q94F62) was performed with the program MODELLER using the BRI1 and PGIP structures as template. Structure-based sequence alignments were done using T-COFFEE (Notredame et al., J. Mol. Biol. 302, 205-217 (2000)). BRI1 and BAK1 share −35%, PGIP and BAK1 share −31% sequence identity, with the LRR and N-cap consensus sequences being highly conserved.
The BRI1 ectodomain (residues 29-788) was expressed in baculovirus-infected insect cells and the secreted protein was purified by tandem-affinity and size-exclusion chromatography. Crystals diffracted to 2.5 Å resolution, and the structure was solved by single isomorphous replacement (see Table 1 and
Such twisted assemblies of LRRs have been observed previously with bacterial effector (Evdokimov et al., J. Mol. Biol. 312, 807-821 (2001)) and adhesion proteins (Schubert et al., Cell 111, 825-836 (2002)), and with the plant defense protein PGIP (
The N- and C-terminal flanking regions that cap the hydrophobic core of the BRI1 solenoid are similar to caps previously described for PGIP (
(%)
)
As defined in XDS
As defined in phenix.refine
indicates data missing or illegible when filed
The island domain in BRI1 corresponds to a large insertion in the regular repeat-structure between LRRs 21 and 22 (residues 584-654) (
We next solved a 2.5 Å co-crystal structure with brassinolide, a potent brassinosteroid that binds BRI1 with nanomolar affinity. Difference density accounting for one molecule of brassinolide per BRI1 monomer was found in close proximity to the island domain (
The steroid-complex reveals a hormone-binding site that involves a much larger portion of the LRR domain than expected. Major interactions between the steroid and the BRI1 LRR domain originate from the very C-terminal LRRs 23-25, which brings the hormone in close proximity to the membrane (
We observed electron density for nine N-glycosylation sites (Asn112, Asn154, Asn233, Asn275, Asn351, Asn401, Asn438, Asn545, Asn575). Particularly well ordered glycans are found at Asn154 and Asn275, which map to the interior of the superhelix and may have a role in structural stabilisation (
Four known BRI1 missense alleles map to the inner surface of last five LRRs (
BRI1 has been reported to form homooligomers in plants (Wang et al., Dev. Cell 8, 855-865 (2005); Hink, Biophys. J. 94, 1052-1062 (2008); Russinova et al., Plant Cell 16, 3216-3229 (2004)). The steroid binding to the island domain and the concomitant rearrangements of the island domain loop could induce a conformational change in a preformed BRI1 homodimer, or allow for ligand-dependent dimerization of the BRI1 ectodomain. However, models of BRI1 dimers that bring the C-termini of their ectodomains into close proximity encounter steric clashes with the N-terminal LRRs (
The present analyses show that the superhelical BRI1 LRR domain alone has no tendency to oligomerize, indicating that BRI1 receptor activation is not be mediated by ligand-induced homodimerization of the ectodomain (as described for TLRs) or by conformational changes in preformed homodimers. The present structures indicate that homooligomerization of BRI1 is constitutive on some level, and independent of ligand stimulus. The presence of an interaction platform that undergoes conformational changes upon steroid binding, and that harbors several loss- and gain-of-function alleles, indicates that another factor controls activation of BRI1.
The present results indicate that the superhelical shape of the BRI1 ectodomain is incompatible with homodimerization, and that the isolated ectodomain behaves as a monomer even in the presence of steroid. This finding indicates that another protein factor binds to the interaction platform in BRI1, e.g., encompassing the steroid ligand, LRRs 21-25, and parts of the island domain (
At least two BAK1-like proteins interact with BRI1 in vivo (He et al., Curr. Biol. 17, 1109-1115 (2007); Karlova et al., Plant Cell 18, 626-638 (2006)). The BRI1 inhibitor protein BKI1 blocks the interaction between the BAK1 and BRI1 kinase domains (Jaillais et al., Genes Dev. 25, 232-237 (2011)). In addition, transgenic lines that constitutively deliver BKI1 to the site of BRI1 signaling resemble strong BRI1 loss-of-function mutants. The results support the role of BAK1 in co-activating BRI1.
The present application claims priority to U.S. Provisional Patent Application No. 61/487,120 filed May 17, 2011, the disclosure of which is incorporated herein by reference in its entirety.
The invention was made with Government support under Grant No. IOS-0649389 awarded by the National Science Foundation, and Grant Nos. AI042266 and P30 NS057096 from the National Institutes of Health. The Government has certain rights in the invention.
| Number | Date | Country | |
|---|---|---|---|
| 61487120 | May 2011 | US |
